Kärppä M, Ning X, Galic M, et al, Reduction in the number of headache hours and days with fremanezumab in patients with migraine and documented inadequate response to 2-4 migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study. 5th European Academy of Neurology (EAN) Congress, abstract EPO3096.
Persoonlijke factoren en ernst ongeval bepalen gevolgen licht hersenletsel
jun 2017